Much of modern medical practice is aimed at the restoration of function by the replacement of damaged tissues or organs either by using artificial implants or by the transplantation of tissues.
1 Such interventions are hindered by factors such as immune rejection, limited supply and morbidity of the donor site. Ideally, skeletal reconstruction depends on the regeneration of normal tissues from the initiation of activity of progenitor cells. However, knowledge is limited as to the origins and phenotypic characteristics of these progenitors and the controlling factors which govern the formation and remodelling of bone. 2 Current procedures include the use of cultured cartilage cells for articular defects. 3 Autologous chondrocyte transplantation is becoming an established technique for the repair of defects in a joint surface. Articular chondrocytes are obtained arthroscopically, expanded in vitro and then reinjected into the defect. However, cell expansion of mature articular chondrocytes is restricted in that it is limited by cell senescence, and expansion in monolayer cultures often induces de-differentiation, hence the need to develop the ability to ensure a phenotypically stable population of expanded articular chondrocytes. 3 Tissue engineering is a multidisciplinary area of research aimed at the regeneration of tissues and the restoration of the function of organs by the implantation of cells or tissues grown outside the body, or by the stimulation of cells to grow into an implanted matrix. 4 The general principle of tissue engineering involves the combination of living cells with a natural or synthetic support, or scaffold, to produce a three-dimensional living tissue construct which is functionally, structurally and mechanically equal to, if not better than, that which it has been designed to replace. 4 Tissues can be designed to grow in such a way that they precisely match the requirements of the individual in terms of size, shape and immunological compatibility, minimising the need for further treatment. The steps involved in the engineering of tissues and organs are the harvesting of cells from the donor site, the seeding of them on to a scaffold, the stimulation of cellular proliferation, the maintenance or stimulation of cellular specialisation or differentiation, and finally, the transplanting of the living tissue or organ into the patient. The object is to combine these elements to create stable, complex three-dimensional constructs of clinically useful size in vivo.
In order to achieve an effective, long-lasting and stable repair of damaged or diseased tissues there are a number of criteria which must be satisfied. These include:
1) The generation of adequate numbers of cells and tissue to fill the defect or complete the repair.
2) The differentiation of the cells towards the correct phenotype and the maintenance of this.
3) Ensuring that the cells or tissues adopt the appropriate three-dimensional organisation and produce extracellular matrix. This may require provision of structural support in the shape of a resorbable scaffold.
4) The production of cells or tissues which are structurally and mechanically compliant with the normal demands of the native tissue.
5) The achievement of full integration with local tissue with vascularisation, if required. 6) Overcoming the risk of immunological rejection.
The ability to satisfy these criteria is largely dependent on the quality of the starting materials and a suitable supply of cells. There are a number of different sources of cells which can be used for tissue repair and regeneration. These include mature cells from the patient, 'adult' stem cells, such as bone marrow stromal or mesenchymal stem cells, and embryonic stem (ES) or germ (EG) cells.
While mature cells which have been isolated from tissue biopsies can potentially be used for re-implantation into the same donor, thus overcoming the need for immunosuppression, they are not the best source of cells for tissue repair. They are generally differentiated cells which have low proliferative potential and therefore the generation of sufficient numbers of cells to promote tissue repair can be potentially difficult. These cells are also usually committed to a particular cell lineage or phenotype which is restricted to the type of tissue from which they have been harvested. This therefore raises problems concerning the accessibility of tissue sites from which cells can be harvested. The patient may have to undergo an invasive procedure, namely bone marrow aspirate, which may have associated complications and morbidity.
Stem cells
Stem cells can overcome many of the limitations of mature cells and there is much interest in their use for tissue repair.
A stem cell is an 'immature' or undifferentiated cell which is capable of producing an identical daughter cell. 5, 6 Self-renewal of stem cells may be perpetuated over many generations resulting in considerable amplification of their numbers. They may remain dormant or quiescent for prolonged periods until they are exposed to a particular stimulus. A stem cell is able to produce at least one and often many types of highly-differentiated cell. A simplified overview of the fate of stem cells is given in Figure 1 , which also helps to illustrate the concept of the potency of stem cells and of the range of cell phenotypes to which they can give rise. There are three basic measures of the potency of stem cells: i) totipotent, which can form all the cells and tissues that contribute to the formation of an organism (eg the fertilised egg or zygote); ii) pluripotent, which can form most, but not all cells or tissues of an organism (eg ES cells and EG cells); and iii) multipotent, which can form a small number of cells or tissues that are usually restricted to a particular germ layer, as seen in bone marrow stromal or mesenchymal stem cells.
This classification of the potency of stem cells is not rigid. The distinction between pluripotent and multipotent is becoming increasingly blurred with some cells having greater plasticity than has been previously realised. The potency of the stem cell is dependent to a large extent on its genetic make-up and whether it is able to activate the appropriate genetic programme to make a particular type of cell. It is also influenced by the environment in which the cell is placed. For example, changes in cytokine gradients and in cell-to-cell and cell-to-marrow contact are important in the switching 'on' and 'off' of genes and gene pathways, thereby controlling the type of cell which is generated.
The location, isolation and derivation of stem cells also need to be considered. The characteristics which make stem cells an 'attractive proposition' for tissue repair and regeneration have been outlined, 4 but reliable sources for obtaining sufficient numbers of stem cells are required. There are mechanisms which activate stem cells or progenitor cells to replace damaged cells. In tissue such as bone, blood and skin with high rates of attrition, the ability to maintain these tissues throughout most of our life span is indicative of the presence of stem cells or progenitor cells which are able constantly to replace damaged cells and repair tissues, 6 thus providing potential sites from which stem cells may be harvested.
Sources of stem cells
There are a number of sources of stem cells which are potentially available for use in tissue repair regeneration. Somatic (adult) stem cells. These are found in specific niches or tissue compartments in the body and are important for maintaining the integrity of tissues such as skin, bone and blood. 5, 6 They include haematopoietic stem cells, 7 bone-marrow stromal (mesenchymal) stem cells (MSC), 8 neural stem cells, 9 dermal (keratinocyte) stem Diagram of a simplified overview of the fate of stem cells. These are capable of potentially unlimited self-renewal and can also give rise to successively more differentiated progeny which usually involves the generation of various progenitors and precursor cells. The type and number of lineages to which a stem cell can give rise are determined by the genetic characteristics of the stem cell (eg pluripotent) and by the environment in which it is placed, including cytokine gradients and cell-to-cell interactions.
cells, 10 stem cells from foetal cord blood 11 and several others. The best characterised are those derived from the bone marrow which yields two types, the haematopoietic stem cell which gives rise to the entire blood cell lineage and the mesenchymal stem cell from which are derived various connective tissues such as bone and adipose tissue.
Mesenchymal stem cells grown in vitro are capable of self-renewal for many generations without significant loss of their characteristics. They are also able to generate several distinct phenotypes including osteoblasts, chondrocytes and adipocytes by relatively simple manipulation of the conditions of culture and of biochemical supplements to which they are exposed and maintained. These qualities have allowed their use in the repair of large osseous defects which are too large to be repaired by endogenous repair mechanisms after implantation into animal models, usually with some form of scaffold. 12 An alternative approach has led to the generation of fully-vascularised bone flaps of the desired shape in vivo, before their use for local transplantation. In these procedures mesenchymal stem cells are loaded into appropriate carriers and transplanted into a non-skeletal site surrounding an artery or vein. Generation of a vascularised segment of bone then takes place, the size and shape of which are dictated by the carrier geometry. 13 Mesenchymal stem cells have also been used in the treatment of children suffering from osteogenesis imperfecta 14 in whom the bone is extremely brittle largely due to the synthesis by the osteoblasts of a defective form of collagen-I, which is the major protein present in bone. The children received allogeneic bone-marrow transplants after ablation of their own marrow. After a few weeks there was a significant improvement in the amount and quality of the bone formed indicating the ability of the mesenchymal cells in the graft to generate osteoblasts capable of synthesising normal bone matrix. Such cells could be transplanted locally to the site of a fracture or deformity in fibrous dysplasia of bone, which results from activating missense mutations of the GNAS1 gene. The possibility of transplantation in utero has been further explored, but only in animal models.
There is evidence which indicates that somatic stem cells isolated from various tissues or niches have greater plasticity and are capable of forming a more diverse range of cell types than has been previously suspected. Mesenchymal stem cells transplanted into rat brain have been shown to acquire a neural phenotype. 15 Marrow stem cells, possibly both stromal and haematopoietic components, have been shown to contribute to the hepatocyte phenotype in man 16 and the myocardium in rats. 17 There appeared to be active targeting of these cells to the heart after they were infused into the blood of animals with hearts which had been damaged experimentally. A further demonstration of the potency of marrow stem cells has come from a study in mice in which the progeny of a single marrow stem cell injected into a mouse were found to contribute to lung, liver, skin and intestine as well as to bone and blood. 18 Adult neural stem cells have been shown to contribute to the haematopoietic lineage 19 and stem cells isolated from adipose tissue have generated bone, cartilage and muscle phenotypes. 20 These observations indicate that somatic stem cells are pluripotent and are influenced by their environment. Marrow stem cells within the marrow space do not make neural cells or hepatocytes, but once transplanted to the brain or liver, seem to respond to that environment and acquire neural or hepatocytic functions. Adult stem cells appear to be able to migrate towards and to take up residence in a tissue which has been damaged in some way and contribute to its repair and regeneration. These attributes have suggested that adult stem cells can suffice as a cell source for promoting tissue repair and negate the need to explore alternatives such as ES cells. 21 More recent studies have shown that a small population of adherent cells isolated from mesenchymal stem cells can be grown almost indefinitely in vitro and can retain the ability to contribute to the differentiation of all somatic cell types when injected into embryos of mice. 22, 23 These experiments identify mesenchymal stem cells as being pluripotent as are ES cells. However, recent studies have questioned the extent of plasticity of the somatic stem cell and whether the ability to generate neural or hepatic cell types represents true differentiation of these cells or cell fusion. It has been shown that fusion is a fairly common event in vitro and in vivo, and results from the fusion of a somatic stem cell with another cell type to create a hybrid. Molecules from one fusion partner may then reprogramme gene expression in the genome of the other partner. 24 How extensive this phenomenon is or whether it has any deleterious effects remains to be evaluated, but when considered from the standpoint of tissue engineering, it raises important questions concerning the plasticity of somatic stem cells and their application to the repair of damaged tissues.
The use of skeletal precursor cells, such as mesenchymal stem cells derived from bone marrow to repair cartilage and other skeletal defects, is an attractive proposition. The evidence noted above supports the hypothesis that multipotent stem cells are available in different organs and tissues and can replace differentiated cells lost to physiological turnover, injury and senescence. Mesenchymal stem cells have the potential to differentiate into lineages of mesenchymal tissue, including cartilage, bone, fat and muscle. A population of such multipotent cells has been derived from adult human synovial membrane and can be induced to differentiate into chondrogenesis, myogenesis, osteogenesis and adipogenesis. 25 At present the use of mesenchymal stem cells is restricted by insufficient knowledge concerning the long-term stability of the repair tissue and by their tendency to differentiate towards other lineages. Their multilineage potential may represent a heterotopic tissue formation and a tendency towards mineralisation and ossification has been demonstrated when periosteum or bone marrow-derived mesen-THE JOURNAL OF BONE AND JOINT SURGERY chymal cells or periosteal and perichondral grafts have been used.
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Embryonic stem cells. These are isolated from the inner cell mass of the blastocyst before implantation 27, 28 and have been derived from mice, non-human primates and man. They are pluripotent cells which retain the capacity to generate any and all foetal and adult cell types in vivo and in vitro. [29] [30] [31] In the presence of leukaemia inhibitory factor (LIF) or embryonic fibroblasts, these cells can be maintained and expanded in vitro in an undifferentiated, pluripotent state almost indefinitely, [29] [30] [31] providing a potentially unlimited source of stem cells. On withdrawal of LIF, the cells spontaneously differentiate to form distinct cellular aggregates or embryoid bodies, which contain differentiating cells of ectodermal, endodermal and mesodermal lineage. [29] [30] [31] By manipulating the culture conditions under which ES cells differentiate, it has been possible to control and restrict the differentiation pathways and thereby generate cultures enriched for lineage-specific precursors. Utilising this approach, ES cells in mice have been used to generate a range of distinct phenotypes including haematopoietic precursors, 32 Developments in the manipulation of ES cells have been studied mostly in mice. However, the recent isolation of such cells in man 28 has created the realistic opportunity that they can be developed for use in tissue repair and regeneration. Although there are differences in the morphology, propagation and culture requirements for maintaining ES cells in the mouse and in man, 28 they are broadly similar in their potential to differentiate into specific cell types. 28, 41 Control of cell differentiation and the preferential selection of one particular phenotype can be achieved by a variety of routes (Fig. 2) . A relatively simple approach is to culture them in media supplemented with cytokines, hormones or other factors which may be expected to stimulate the cell type of interest. Detailed knowledge of the biology of the cell type is required but biochemical selection is relatively effective. It is possible to demonstrate the derivation of osteoblasts by simply maintaining dispersed mouse embryoid bodies in a culture medium which has been used routinely to culture explanted mouse osteoblasts. While the biochemical composition of the medium in which the differentiating ES cells are maintained is an import stimulus for selecting the osteoblast phenotype, the timing of stimulation is also crucial. 39 Delaying the addition of dexamethasone for up to 14 days after dispersal and culture of the embryoid bodies resulted in a sevenfold enrichment of cells capable of expressing the osteoblast phenotype.
Co-culture with mouse osteoblasts is also an effective inducer of osteogenic differentiation in ES cells. 39 There are unpublished reports which are said to show that implantation of human ES cells into mouse organs and tissues, including brain and liver, is an effective method for inducing neural or hepatic phenotypes. Such observations are consistent with those in adult stem cells and further emphasise the influence of the environment on stem cells and the acquisition of a particular phenotype.
Biochemical selection, although a useful method for generating in vitro cultures enriched with a particular phenotype, is not generally sufficiently effective to exclude other phenotypes. Methods to further purify or select cells of the desired phenotype need to be developed if ES cells are to be considered for use in transplantation. Methods such as fluorescence-activated cell sorting or magnetic-activated cell sorting are extremely useful in sorting and purifying a particular cell type or population. A cell-surface marker is expressed by the cell type of interest and can be recognised by a fluorescence or magnetic microbead tagged antibody. It is then use preferentially to sort that cell. The cell-surface marker needs to be unique to the desired cell lineage and should not be sensitive to activation upon binding of the tagged antibody. Both of the methods described above have been used to purify osteoprogenitors from marrow stromal stem cells.
As an alternative, both ES and somatic stem cells can be transduced with a lineage-specific gene. The gene insert can also carry one of several resistance genes which allows for preferential selection of cell subpopulations that are restricted to the lineage of interest. This method has been used to select neural 34 and cardiomyocyte phenotypes. 36 In the latter case the selected cardiomyocytes were subsequently implanted into the damaged hearts of mice and were shown to form stable grafts. 36 The potential applications of ES cells for tissue repair and regeneration are further enhanced by the possibility of using nuclear transfer to render these cells autologous and thus remove risks of tissue rejection, or by the use of human ES cell lines with modification of the major histocompatibility complex. 42 The major concern with ES cells relates to the ethics of their creation and the proposed practice of therapeutic cloning. However, many of the embryos created by in vitro fertilisation programmes are surplus to requirements and are normally destroyed. These could potentially be used for the derivation of ES cells.
The means of delivering factors to stimulate stem cells in vivo to initiate a process leading to regeneration has long been sought. Success has been limited by problems of dosage, lack of full activity of recombinant factors and the inability to sustain the presence of the factor for an appropriate length of time. 'Gene-activated matrices' are being investigated which compromise plasmids coding for factors in a variety of delivery vehicles. These would transduce cells in vivo to bring about appropriate regeneration, and trials aimed at treated osteoporotic fractures are currently being planned. Other sources of pluripotent stem cells include EG cells 43 derived from the gonadal ridge of the early foetus or embryonic carcinoma cells derived from teratocarcinomas. 44 These are important cell sources which could be used therapeutically or as models to investigate further the mechanisms of pluripotency and lineage-restricted differentiation. The risk of forming unwanted tissues or even teratocarcinomas by both adult and ES cells also needs to be fully evaluated. However, in recent studies human ES cells have been engineered to express a suicide gene, which rendered the cells susceptible to a particular drug. Using this approach these cells and their differentiated progeny could be successfully ablated in vivo when implanted in a mouse model, and this may provide a means to check the growth of any unwanted or unexpected tissues. 45 The prospect of stem-cell-mediated gene therapy is also apparent and with this the definition of tissue engineering evolves into engineering of tissue function. Approaches to tissue reconstruction based on the use of stem cells open up wide potential applications. Enthusiasm for this markedly innovative technique with huge therapeutic potential must be balanced against stringent standards of scientific and clinical investigation.
